Selected Start-Ups (5/01)
In Vivo summarizes the technology of several recently founded companies: Aptus Genomics Inc. is developing a platform to identify, qualify, and patent human cell surface receptor genes. Raven Biotechnologies Inc. spin-off bioMosaic Systems Inc. will develop Raven's CellArray cell-based high-throughput screening system. IntelliServices Inc. is building a suite of ASP-based software solutions for physicians. Spine Wave Inc. will develop and commercialize a minimally-invasive method for spinal disc repair. 20/20 Gene Systems Inc. is building protein analysis tools for determining the molecular fingerprint of a patient sample and comparing it to archived information from a larger patient population. Xcel Pharmaceuticals Inc. will in-license pharmaceuticals for niche therapeutic markets, initially focusing on neurology.
You may also be interested in...
FDA concluded that original formulation of brain hemorrhage treatment was not discontinued for safety or effectiveness reasons, saying Arbor had other options to reduce risk of confusion between the new and original formulations. But the sponsor argues that withdrawal was part of FDA-approved risk mitigation plan.
Despite AI and digital analytics playing an increasing role in pharma, the industry lags others globally, a recent event heard. Meanwhile, top Indian players including Sun Pharma, Cipla and others shared what is driving their initiatives, ranging from a 'touchless factory' to virtual training and lessons learned along the way.
Hologic made its third big acquisition of 2021 and Agilent agreed to pay up to $695m for Resolution Bioscience to extend its precision oncology capabilities.